Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of …

Background: Contemporary guidelines for managing nonvalvular atrial fibrillation (NVAF)
include apixaban and rivaroxaban as first-line anticoagulation treatment options. Minimal …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Background There are limited data regarding clinical outcomes and healthcare resource
utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are …

Anticoagulation therapy is recommended for patients with non-valvular atrial fibrillation
(NVAF) and an increased risk of stroke. Although apixaban showed superiority over warfarin …

Background Current evidence suggests that rivaroxaban may be well tolerated and effective
in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited …